CRNX vs ODTX
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. ODTX: A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
Side-by-side fundamentals
| Metric | CRNX | ODTX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $83.52 | $18.93 | |
| Market cap as of 2026-08-03 | $8.8B | $909M | |
| PEG as of 2026-08-03 | -0.47 | n/a | |
| Net margin as of 2026-08-03 | -2747.2% | -3822.7% | CRNX higher |
| Gross margin as of 2026-08-03 | +86.0% | n/a | |
| Operating margin as of 2026-08-03 | -3020.3% | -4010.4% | CRNX higher |
| ROE as of 2026-08-03 | -44.0% | -69.0% | CRNX higher |
| ROA as of 2026-08-03 | -39.6% | -55.1% | CRNX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-03 | +2277.5% | -19.0% | CRNX higher |
| Beta as of 2026-08-03 | 1.10 | 0.16 | |
| 1-year return as of 2026-07-31 close | +192.1% | n/a |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.